Searched for
SUN PHARMA RANBAXY
Sun Pharma-Organon deal: How a $12-billion merger will reshape India's pharma landscapeSun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The ...- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Sun's strong gravity helps India Inc's pullSun Pharma has expanded its horizons by acquiring Organon, a notable New Jersey pharmaceutical firm. This strategic acquisition fortifies S...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- Ranbaxy India head Rajeev Sibal latest to quitSibal, a pharma industry veteran, is expected to join drug company Lupin later this month.
- Sun-Ranbaxy $4 billion merger completedSun Pharmaceutical Industries today said merger of Ranbaxy with itself has been 'consummated' following receipt of requisite approvals.
- Sun-Ranbaxy $4 billion deal: US anti-trust regulator FTC passes final orderFTC has passed its final order settling charges that Sun Pharma's $4 billion deal to acquire Ranbaxy Laboratories could result in unfair bu...
- Sun Pharma executives bag top slots in company after Ranbaxy mergerMost executives from Ranbaxy's earlier team have already left the company in past one year.
- Sun Pharma-Ranbaxy merger may put pressure on Ebitda margins of merged entity: Daljeet Singh KohliHow Sun Pharma integrates its business will be keenly followed, says Kohli. Merged entity will take some time to derive synergistic benefit...
- Ranbaxy and Sun Pharma appoint Ranjan Chakravarti as integration committee head; to identify areas of synergiesSun Pharma and Ranbaxy Labs, the rival it is in the process of acquiring, have set up an integration committee headed by Ranjan Chakravarti
- Andhra Pradesh High Court verdict on Sun Pharma-Ranbaxy merger plea tomorrowAfter hearing the arguments from the counsels of the petitioners, Ranbaxy, Sun Pharma and SEBI, Justice G Chandraiah said he will pronounce...
- Andhra HC verdict on Sun Pharma-Ranbaxy merger plea tomorrowThe court had earlier issued interim orders to maintain status quo with regard to the merger.
- Sun Pharma vows 'appropriate action' as merger haltedSun Pharma said it will take "appropriate action" in the wake of AP High Court suspending the co's $4 bn deal with Ranbaxy.
- Sun Pharma to make Rs 18 crore open offer to Zenotech shareholdersSun Pharma will make an open offer worth Rs 18.4 crore to acquire a little over 28 per cent stake in Zenotech Laboratories Ltd.
- Sun Pharma denies insider trading charges in Ranbaxy dealSun Pharma denied insider trading charges against Silverstreet Developers- its wholly owned arm - in the $4 bn acquisition deal of Ranbaxy ...
- Sun Pharma rallies over 8%, breaches Rs 600 levels on Ranbaxy deal; top Sensex gainerAnalysts are betting around 20% return from the stock in the medium term. They say the stock could double investor wealth in two years.
- Sun Pharma-Ranbaxy, Holcim-Lafarge deals to face intense regulatory scrutinySebi would be closely looking at the Sun Pharma-Ranbaxy deal to ensure compliance with stringent norms that are in place for listed entitie...
- Merger with Sun Pharma will spell the end of Ranbaxy brand, but a new dawn beckonsSun Pharma may not have to face surprises emanating from Ranbaxy. There is every likelihood that brand Ranbaxy will see a sunset clause whe...
- Sun Pharma to buy Ranbaxy in $3.2 bn deal: HighlightsSun Pharmaceutical Industries said that it will buy generic drug maker Ranbaxy Laboratories, has hit regulatory snags in its key US market ...
Load More
